体外診断薬の世界市場：製品・サービス別、技術別、検体別、検査場所別、用途別、エンドユーザー別、地域別 - 2030年までの予測

世界の体外診断薬の市場規模は、2025年の1,090億6,550万米ドルから2030年には1,576億3,250万米ドルに達すると予測され、予測期間中のCAGRは7.6%と見込まれています。

この背景には、糖尿病、心血管疾患、がん、感染症（HIV、結核など）といった慢性疾患の世界の負担増があります。迅速な検査結果、分散型検査、在宅診断への需要がポイントオブケア（POC）検査機器の成長を後押ししており、ハイスループット・システム、ラボオンチップ、次世代シーケンシング（NGS）、POC診断などのイノベーション、新興経済諸国を中心としたヘルスケアインフラへの政府・民間セクターの投資が診断サービスへのアクセスを改善しています。

体外診断薬市場は、製品別に試薬＆キット、機器、データ管理ソフトウェア＆サービスに分けられます。2024年、試薬＆キット分野は体外診断薬市場で最も高いCAGRで成長しました。この背景には、病院、ラボ、家庭での検査件数の増加、迅速検査キットや自己検査キットの拡大、特にグルコース、妊娠、感染症検出の拡大、臨床検査室、診断チェーン、POC検査環境の拡大による試薬使用量の増加があります。CE-IVDマーキングやFDAクリアランスなど、継続的な製品の上市と規制当局の承認により、様々な臨床用途に特化した検査キットのポートフォリオとアクセシビリティが拡大しています。

用途別に見ると、体外診断薬市場は感染症、腫瘍、内分泌、循環器、血液スクリーニング、遺伝子検査、自己免疫疾患、アレルギー診断、薬物モニタリング・検査、骨・ミネラル障害、凝固検査、血液型タイピング、その他に区分されます。感染症分野は、HIV、肝炎、結核のような疾病の継続的な流行、マラリアやMpoxのような新たな脅威、迅速な検査の必要性、アクセス可能な検査、特に遠隔地や僻地での検査の必要性から、体外診断薬市場で最大の市場シェアを占めている、また、RT-PCR（逆転写ポリメラーゼ連鎖反応）やシンドロミックパネル検査などの技術は、複数の病原体の正確でハイスループットな診断を可能にし、病院や研究所の環境における成長を促進しています。

世界の体外診断薬市場は、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ、GCCの6つの主要地域に区分されます。アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予測されています。アジア太平洋のIVD市場は、特に中国やインドのような人口の多い国々で、伝染性疾患や非伝染性疾患の有病率の増加により急成長しています。これらの国々では、糖尿病、がん、心血管疾患、結核、肝炎などの疾患が増加しています。同時に、高齢化がアジア太平洋地域、特に日本、韓国、中国のIVD市場を牽引しています。例えば、中国では65歳以上の高齢者が2億1,676万人で、人口の15.4%を占めていると、中国民政部と中国高齢化委員会の2023年報告書は述べています。この動向により、慢性疾患のモニタリングや定期的な診断に対する需要が高まっています。現地生産を増やし、輸入への依存を減らすため、地方政府は診断試薬、キット、機器の現地生産を推進しており、市場の成長も促進しています。

当レポートでは、世界の体外診断薬市場について調査し、製品・サービス別、技術別、検体別、検査場所別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

• イントロダクション
• 市場力学
• 顧客ビジネスに影響を与える動向/混乱
• 価格分析
• バリューチェーン分析
• サプライチェーン分析
• エコシステム分析
• 投資と資金調達のシナリオ
• 技術分析
• 特許分析
• 貿易分析
• 2025年～2026年の主な会議とイベント
• ケーススタディ分析
• 規制状況
• 規制枠組み
• ポーターのファイブフォース分析
• 主要な利害関係者と購入基準
• 米国市場における最近の政策変更と承認プロセスへの潜在的な影響
• 医療技術企業のサプライチェーンのレジリエンスに対する関税の影響
• 分散型テストの成長と費用対効果の高い集中型テストの採用
• AI/生成AIが体外診断薬市場に与える影響

第6章 体外診断薬市場（製品・サービス別）

• イントロダクション
• 試薬・キット
• 機器
• データ管理ソフトウェアとサービス

第7章 体外診断薬市場（技術別）

• イントロダクション
• 免疫アッセイ
• 臨床化学
• 分子診断
• 血糖モニタリング
• 血液学
• 微生物学
• 凝固と止血
• 血液ガス分析装置
• 尿検査
• クロマトグラフィと質量分析

第8章 体外診断薬市場（検体別）

• イントロダクション
• 血液、血清、血漿検体
• 唾液検体
• 尿検体
• その他

第9章 体外診断薬市場（検査場所別）

• イントロダクション
• 臨床検査
• ポイントオブケアテスト

第10章 体外診断薬市場（用途別）

• イントロダクション
• 感染症
• 腫瘍学
• 内分泌学
• 心臓病学
• 血液検査
• 遺伝子検査
• 自己免疫疾患
• アレルギー診断
• 薬物モニタリングと検査
• 骨およびミネラル疾患
• 凝固検査
• 血液型判定
• その他

第11章 体外診断薬市場（エンドユーザー別）

• イントロダクション
• 病院とクリニック
• 臨床検査室
• 血液バンク
• 在宅医療
• 製薬・バイオテクノロジー企業
• 学術機関
• その他

第12章 体外診断薬市場（地域別）

• イントロダクション
• 北米
  • 北米のマクロ経済見通し
  • 米国
  • カナダ
• 欧州
  • 欧州のマクロ経済見通し
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • スイス
  • その他
• アジア太平洋
  • アジア太平洋のマクロ経済見通し
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • シンガポール
  • その他
• ラテンアメリカ
  • ラテンアメリカのマクロ経済見通し
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 出生前検査とがん検査への注目が高まり市場を牽引
  • 中東・アフリカ：マクロ経済見通し
• GCC諸国
  • GCC諸国：マクロ経済見通し
  • サウジアラビア
  • アラブ首長国連邦
  • その他

第13章 競合情勢

• 概要
• 主要参入企業の戦略/強み
• 主要参入企業が採用した戦略の概要
• 収益分析、2022年～2024年
• 市場シェア分析、2024年
• 企業評価と財務指標
• ブランド/製品比較
• 企業評価マトリックス：主要参入企業、2024年
• 企業評価マトリックス：スタートアップ/中小企業、2024年
• 競合シナリオ
• IVD市場で事業を展開する主要企業の将来的な戦略の可能性

第14章 企業プロファイル

• 主要参入企業
  • DANAHER
  • F. HOFFMANN-LA ROCHE LTD
  • ABBOTT
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.
  • HOLOGIC, INC.
  • BIO-RAD LABORATORIES, INC.
  • BIOMERIEUX
  • SYSMEX CORPORATION
  • REVVITY
  • BECTON, DICKINSON AND COMPANY
  • AGILENT TECHNOLOGIES, INC.
  • QIAGEN
  • DIASORIN S.P.A.
  • GRIFOLS, S.A.
  • WERFEN
  • QUIDELORTHO CORPORATION
• その他の企業
  • DEVYSER
  • BIOSYNEX SA
  • SURMODICS, INC.
  • MENARINI SILICON BIOSYSTEMS
  • SPEEDX PTY. LTD.
  • GENSPEED BIOTECH GMBH
  • MERCK KGAA
  • CARIS LIFE SCIENCES
  • ARKRAY, INC.
  • ACCELERATE DIAGNOSTICS, INC.
  • CELLABS
  • J. MITRA & CO. PVT. LTD.
  • EPITOPE DIAGNOSTICS, INC.
  • BOSTER BIOLOGICAL TECHNOLOGY
  • ENZO BIOCHEM INC.
  • GENETIC SIGNATURES
  • SAVYON DIAGNOSTICS
  • TRIVITRON HEALTHCARE
  • MDXHEALTH
  • CREATIVE DIAGNOSTICS
  • INBIOS INTERNATIONAL, INC.
  • MACCURA BIOTECHNOLOGY CO., LTD.
  • LUYE LIFE SCIENCES GROUP

第15章 付録

List of Tables

• TABLE 1 IN VITRO DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 IN VITRO DIAGNOSTICS MARKET: RISK ASSESSMENT
• TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022-2050
• TABLE 4 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2022-2024
• TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
• TABLE 6 RECENT DEVELOPMENTS IN IVD MARKET, 2021-2023
• TABLE 7 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
• TABLE 8 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022-2024 (USD)
• TABLE 9 AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY TYPE, 2022-2024 (USD)
• TABLE 10 IN VITRO DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 11 IN VITRO DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022-2024
• TABLE 12 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION)
• TABLE 13 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2024 (USD MILLION)
• TABLE 14 IN VITRO DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
• TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 19 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 20 US: CLASSIFICATION OF IVD DEVICES
• TABLE 21 EUROPE: CLASSIFICATION OF IVD DEVICES
• TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
• TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 24 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 25 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 26 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
• TABLE 27 RUSSIA: CLASSIFICATION OF IVD DEVICES
• TABLE 28 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 29 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
• TABLE 30 IN VITRO DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%)
• TABLE 32 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
• TABLE 33 US: OVERVIEW OF CERTAIN KEY CATEGORIES OF IVD DEVICES
• TABLE 34 TARIFF RATES IMPOSED BY US, AS OF APRIL 2025
• TABLE 35 COMPARATIVE ANALYSIS OF CENTRALIZED VS. DECENTRALIZED TESTING
• TABLE 36 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 37 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 38 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 39 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 41 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 42 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 43 KEY IVD INSTRUMENTS AVAILABLE WORLDWIDE
• TABLE 44 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 45 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 46 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 47 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 48 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 49 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 50 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE
• TABLE 51 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 52 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 53 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 54 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 55 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 56 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 57 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 58 KEY IMMUNOASSAY ANALYZERS AVAILABLE WORLDWIDE
• TABLE 59 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 60 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 61 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 62 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 63 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 64 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 65 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 66 KEY ELISA ANALYZERS AVAILABLE WORLDWIDE
• TABLE 67 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 68 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 69 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 70 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 71 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 72 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 73 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE WORLDWIDE
• TABLE 74 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 75 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 76 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 77 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 78 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 79 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 80 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 81 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 82 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 83 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 84 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 85 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 86 KEY RAPID TESTS AVAILABLE WORLDWIDE
• TABLE 87 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 88 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 89 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 90 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 91 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 92 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 93 IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 94 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 95 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 96 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 97 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 98 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 99 KEY WESTERN BLOTTING SYSTEMS AVAILABLE WORLDWIDE
• TABLE 100 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 101 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 102 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 103 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 104 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 105 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 106 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 107 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 108 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 109 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 110 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 111 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 112 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES AVAILABLE WORLDWIDE
• TABLE 113 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES AVAILABLE WORLDWIDE
• TABLE 114 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 151 REFERENCE RANGES AND ABNORMAL CONDITIONS FOR KEY ELECTROLYTES
• TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 153 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 154 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 155 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 156 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 157 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 158 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 159 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 160 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 161 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 162 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 163 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 164 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE WORLDWIDE
• TABLE 165 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 172 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE
• TABLE 173 IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2030 (USD MILLION)
• TABLE 174 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 175 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 176 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 177 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 178 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 179 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE WORLDWIDE
• TABLE 180 IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 181 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 182 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 183 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 184 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 185 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 186 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE WORLDWIDE
• TABLE 187 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 188 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 189 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 190 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 191 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 192 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 193 IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2030 (USD MILLION)
• TABLE 194 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 195 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 196 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 197 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 198 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 199 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 200 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 201 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 202 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 203 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 204 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 205 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 206 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 207 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 208 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 209 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 210 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 211 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
• TABLE 212 IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 213 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 214 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 215 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 216 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 217 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 218 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 219 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 220 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 221 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 222 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 223 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 224 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 225 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 226 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 227 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 228 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 229 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 230 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 231 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 232 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 233 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 234 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 235 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 236 KEY BLOOD GAS ANALYZERS AVAILABLE WORLDWIDE
• TABLE 237 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 238 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 239 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 240 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 241 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 242 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZER, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 243 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 244 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 245 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 246 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 247 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 248 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 249 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 250 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 251 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 252 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 253 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 254 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 255 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 256 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
• TABLE 257 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 258 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 259 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 260 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 261 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 262 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 263 IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 264 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 265 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 266 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 267 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 268 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 269 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
• TABLE 270 IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 271 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 272 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 273 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 274 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 275 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 276 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 277 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 278 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 279 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 280 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 281 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 282 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2022-2030 (USD MILLION)
• TABLE 283 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 291 IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 292 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 293 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 294 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 295 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 296 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 297 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 298 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 299 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 300 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 301 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 302 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 303 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 304 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040
• TABLE 305 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES, 2022-2024
• TABLE 306 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 307 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 308 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 309 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 310 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 311 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 312 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 313 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 314 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 315 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 316 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 317 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 318 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 319 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 320 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 321 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 322 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 323 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 324 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 325 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 326 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 327 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 328 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 329 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 330 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 331 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 332 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 333 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 334 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 335 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 336 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 337 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 338 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 339 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 340 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 341 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 342 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 343 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 344 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 345 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 346 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 347 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 348 KEY PRODUCTS FOR DRUG MONITORING WORLDWIDE
• TABLE 349 KEY IVD PRODUCTS FOR DRUG TESTING WORLDWIDE
• TABLE 350 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 351 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 352 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 353 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 354 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 355 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 356 KEY PRODUCTS FOR BONE & MINERAL DISORDERS WORLDWIDE
• TABLE 357 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 358 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 359 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 360 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 361 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 362 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 363 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 364 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 365 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 366 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 367 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 368 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 369 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2022-2030 (USD MILLION)
• TABLE 370 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 371 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 372 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 373 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 374 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 375 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 376 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 377 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 378 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 379 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 380 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 381 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 382 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 383 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 384 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 385 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 386 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 387 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 388 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 389 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 390 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 391 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 392 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 393 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 394 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 395 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 396 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 397 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 398 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 399 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 400 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 401 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 402 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 403 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 404 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 405 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 406 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 407 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 409 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 410 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 411 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 412 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 413 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 415 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 416 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 417 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 418 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 419 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 420 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 421 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 422 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 423 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 424 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 425 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 426 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 427 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 428 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 429 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 430 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 431 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 432 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 433 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 434 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 435 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 436 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 437 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 438 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 439 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 440 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 441 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 442 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 443 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 444 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 445 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 446 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 447 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 448 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 449 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 450 US: KEY MACROECONOMIC INDICATORS
• TABLE 451 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022-2030 (BILLION)
• TABLE 452 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 453 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 454 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 455 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 456 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 457 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 458 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 459 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 460 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 461 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 462 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034
• TABLE 463 CANADA: KEY MACROECONOMIC INDICATORS
• TABLE 464 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 465 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 466 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 467 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 468 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 469 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 470 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 471 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 472 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 473 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 474 EUROPE: KEY MACROECONOMIC INDICATORS
• TABLE 475 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 476 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 477 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 478 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 479 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 480 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 481 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 482 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 483 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 484 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 485 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 486 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 487 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 488 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 489 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 490 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 491 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 492 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 493 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 494 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 495 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 496 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 497 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 498 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 499 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 500 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 501 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 502 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 503 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 504 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 505 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 506 UK: KEY MACROECONOMIC INDICATORS
• TABLE 507 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 508 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 509 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 510 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 511 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 512 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 513 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 514 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 515 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 516 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 517 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 518 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 519 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 520 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 521 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 522 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 523 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 524 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 525 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 526 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 527 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 528 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 529 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 530 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 531 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 532 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 533 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 534 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 535 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 536 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 537 RUSSIA: KEY MACROECONOMIC INDICATORS
• TABLE 538 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 539 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 540 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 541 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 542 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 543 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 544 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 545 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 546 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 547 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 548 SWITZERLAND: KEY MACROECONOMIC INDICATORS
• TABLE 549 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 550 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 551 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 552 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 553 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 554 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 555 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 556 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 557 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 558 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 559 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 560 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 561 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 562 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 563 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 564 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 565 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 566 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 567 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 568 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 569 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
• TABLE 570 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 571 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 572 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 573 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 574 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 575 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 576 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 577 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 578 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 579 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 580 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 581 JAPAN: KEY MACROECONOMIC INDICATORS
• TABLE 582 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 583 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 584 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 585 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 586 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 587 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 588 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 589 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 590 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 591 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 592 CHINA: KEY MACROECONOMIC INDICATORS
• TABLE 593 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 594 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 595 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 596 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 597 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 598 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 599 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 600 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 601 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 602 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 603 INDIA: KEY MACROECONOMIC INDICATORS
• TABLE 604 INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 605 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 606 INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 607 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 608 INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 609 INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 610 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 611 INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 612 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 613 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 614 SOUTH KOREA: KEY MACROECONOMIC INDICATORS
• TABLE 615 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 616 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 617 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 618 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 619 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 620 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 621 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 622 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 623 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 624 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 625 AUSTRALIA: KEY MACROECONOMIC INDICATORS
• TABLE 626 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 627 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 628 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 629 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 630 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 631 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 632 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 633 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 634 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 635 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 636 SINGAPORE: KEY MACROECONOMIC INDICATORS
• TABLE 637 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 638 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 639 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 640 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 641 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 642 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 643 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 644 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 645 SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 646 SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 647 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 648 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 649 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 650 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 651 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 652 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 653 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 654 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 655 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 656 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 657 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 658 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 659 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 660 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 661 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 662 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 663 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 664 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 665 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 666 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 667 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 668 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 669 BRAZIL: KEY MACROECONOMIC INDICATORS
• TABLE 670 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 671 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 672 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 673 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 674 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 675 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 676 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 677 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 678 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 679 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 680 MEXICO: KEY MACROECONOMIC INDICATORS
• TABLE 681 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 682 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 683 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 684 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 685 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 686 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 687 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 688 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 689 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 690 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 691 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 692 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 693 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 694 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 695 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 696 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 697 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 698 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 699 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 700 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 701 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
• TABLE 702 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 703 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 704 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 705 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 706 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 707 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 708 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 709 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 710 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 711 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 712 GCC COUNTRIES: KEY MACROECONOMIC INDICATORS
• TABLE 713 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 714 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 715 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 716 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 717 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 718 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 719 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 720 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 721 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 722 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 723 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 724 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 725 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 726 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 727 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 728 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 729 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 730 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 731 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 732 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 733 SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 734 UAE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 735 UAE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 736 UAE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 737 UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 738 UAE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 739 UAE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 740 UAE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 741 UAE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 742 UAE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 743 UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 744 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2030 (USD MILLION)
• TABLE 745 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 746 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 747 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 748 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 749 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2030 (USD MILLION)
• TABLE 750 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2030 (USD MILLION)
• TABLE 751 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 752 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 753 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 754 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022-APRIL 2025
• TABLE 755 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
• TABLE 756 IN VITRO DIAGNOSTICS MARKET: REGION FOOTPRINT
• TABLE 757 IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 758 IN VITRO DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
• TABLE 759 IN VITRO DIAGNOSTICS MARKET: END-USER FOOTPRINT
• TABLE 760 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 761 IN VITRO DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• TABLE 762 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 763 IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022-APRIL 2025
• TABLE 764 IN VITRO DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 765 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 766 IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022-MARCH 2025
• TABLE 767 AI-DRIVEN PRODUCTS & SERVICES PROVIDED BY KEY PLAYERS
• TABLE 768 DANAHER: COMPANY OVERVIEW
• TABLE 769 DANAHER: PRODUCTS/SERVICES OFFERED
• TABLE 770 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 771 DANAHER: DEALS, JANUARY 2022-MARCH 2025
• TABLE 772 DANAHER: EXPANSIONS, JANUARY 2022-MARCH 2024
• TABLE 773 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
• TABLE 774 F. HOFFMANN-LA ROCHE LTD: CURRENCY CONVERSION, 2022-2024
• TABLE 775 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
• TABLE 776 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 777 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022-MARCH 2025
• TABLE 778 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022-MARCH 2024
• TABLE 779 ABBOTT: COMPANY OVERVIEW
• TABLE 780 ABBOTT: PRODUCTS/SERVICES OFFERED
• TABLE 781 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 782 ABBOTT: DEALS, JANUARY 2022-MARCH 2025
• TABLE 783 ABBOTT: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 784 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 785 SIEMENS HEALTHINEERS AG: CURRENCY CONVERSION, 2022-2024
• TABLE 786 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
• TABLE 787 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 788 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022-MARCH 2025
• TABLE 789 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 790 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 791 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
• TABLE 792 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 793 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-MARCH 2025
• TABLE 794 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 795 ILLUMINA, INC.: COMPANY OVERVIEW
• TABLE 796 ILLUMINA, INC.: PRODUCTS OFFERED
• TABLE 797 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 798 ILLUMINA, INC.: DEALS, JANUARY 2022-MARCH 2025
• TABLE 799 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 800 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022-MARCH 2025
• TABLE 801 HOLOGIC, INC.: COMPANY OVERVIEW
• TABLE 802 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 803 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 804 HOLOGIC, INC.: DEALS, JANUARY 2022-MARCH 2025
• TABLE 805 HOLOGIC, INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 806 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 807 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 808 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 809 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-MARCH 2025
• TABLE 810 BIOMERIEUX: COMPANY OVERVIEW
• TABLE 811 BIOMERIEUX: CURRENCY CONVERSION, 2022-2024
• TABLE 812 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
• TABLE 813 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 814 BIOMERIEUX: DEALS, JANUARY 2022-MARCH 2025
• TABLE 815 BIOMERIEUX: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 816 SYSMEX CORPORATION: COMPANY OVERVIEW
• TABLE 817 SYSMEX CORPORATION: CURRENCY CONVERSION, 2022-2024
• TABLE 818 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 819 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 820 SYSMEX CORPORATION: DEALS, JANUARY 2022-MARCH 2025
• TABLE 821 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 822 REVVITY: COMPANY OVERVIEW
• TABLE 823 REVVITY: PRODUCTS/SERVICES OFFERED
• TABLE 824 REVVITY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 825 REVVITY: DEALS, JANUARY 2022-MARCH 2025
• TABLE 826 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-MARCH 2025
• TABLE 827 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
• TABLE 828 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
• TABLE 829 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 830 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022-MARCH 2025
• TABLE 831 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 832 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 833 AGILENT TECHNOLOGIES, INC: PRODUCTS/SERVICES OFFERED
• TABLE 834 AGILENT TECHNOLOGIES, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 835 AGILENT TECHNOLOGIES, INC: DEALS, JANUARY 2022-MARCH 2025
• TABLE 836 AGILENT TECHNOLOGIES, INC: OTHER DEVELOPMENTS, JANUARY 2022-MARCH 2025
• TABLE 837 QIAGEN: COMPANY OVERVIEW
• TABLE 838 QIAGEN: PRODUCTS/SERVICES OFFERED
• TABLE 839 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 840 QIAGEN: DEALS, JANUARY 2022-MARCH 2025
• TABLE 841 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 842 DIASORIN S.P.A.: CURRENCY CONVERSION, 2021-2023
• TABLE 843 DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED
• TABLE 844 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 845 DIASORIN S.P.A.: DEALS, JANUARY 2022-MARCH 2025
• TABLE 846 GRIFOLS, S.A.: COMPANY OVERVIEW
• TABLE 847 GRIFOLS, S.A.: CURRENCY CONVERSION, 2022-2024
• TABLE 848 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED
• TABLE 849 GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 850 GRIFOLS, S.A.: DEALS, JANUARY 2022-MARCH 2025
• TABLE 851 WERFEN: COMPANY OVERVIEW
• TABLE 852 WERFEN: PRODUCTS/SERVICES OFFERED
• TABLE 853 WERFEN: DEALS, JANUARY 2022-MARCH 2025
• TABLE 854 WERFEN: EXPANSIONS, JANUARY 2022-MARCH 2025
• TABLE 855 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• TABLE 856 QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 857 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
• TABLE 858 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022-MARCH 2025
• TABLE 859 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022-MARCH 2024
• TABLE 860 DEVYSER: COMPANY OVERVIEW
• TABLE 861 BIOSYNEX SA: COMPANY OVERVIEW
• TABLE 862 SURMODICS, INC.: COMPANY OVERVIEW
• TABLE 863 MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW
• TABLE 864 SPEEDX PTY. LTD.: COMPANY OVERVIEW
• TABLE 865 GENSPEED BIOTECH GMBH: COMPANY OVERVIEW
• TABLE 866 MERCK KGAA: COMPANY OVERVIEW
• TABLE 867 CARIS LIFE SCIENCES: COMPANY OVERVIEW
• TABLE 868 ARKRAY, INC.: COMPANY OVERVIEW
• TABLE 869 ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 870 CELLABS: COMPANY OVERVIEW
• TABLE 871 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
• TABLE 872 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 873 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
• TABLE 874 ENZO BIOCHEM INC.: COMPANY OVERVIEW
• TABLE 875 GENETIC SIGNATURES: COMPANY OVERVIEW
• TABLE 876 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 877 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
• TABLE 878 MDXHEALTH: COMPANY OVERVIEW
• TABLE 879 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 880 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
• TABLE 881 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
• TABLE 882 LUYE LIFE SCIENCES GROUP: COMPANY OVERVIEW

List of Figures

• FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE
• FIGURE 2 RESEARCH DESIGN
• FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 5 GLOBAL IN VITRO DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
• FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 7 TOP-DOWN APPROACH
• FIGURE 8 DATA TRIANGULATION METHODOLOGY
• FIGURE 9 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 10 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• FIGURE 11 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2025 VS. 2030 (USD MILLION)
• FIGURE 12 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 GEOGRAPHIC SNAPSHOT OF IN VITRO DIAGNOSTICS MARKET
• FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING EMPHASIS ON NEED FOR EARLY DIAGNOSIS TO DRIVE MARKET
• FIGURE 17 REAGENTS & KITS SEGMENT AND US LED NORTH AMERICAN IN VITRO DIAGNOSTICS MARKET IN 2024
• FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
• FIGURE 21 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 22 IN VITRO DIAGNOSTIC REGULATION: CRITICAL AREAS OF IMPACT
• FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• FIGURE 24 IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 25 IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 26 IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAPPING
• FIGURE 27 IN VITRO DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2020-2023
• FIGURE 28 IN VITRO DIAGNOSTICS MARKET: PATENT ANALYSIS, 2014-2024
• FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES
• FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
• FIGURE 31 EUROPE: IN VITRO DIAGNOSTIC REGULATION (IVDR) TIMELINE
• FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
• FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
• FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
• FIGURE 35 IN VITRO DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS, BY PRODUCT & SERVICE
• FIGURE 37 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
• FIGURE 38 AI USE CASES
• FIGURE 39 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
• FIGURE 40 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
• FIGURE 41 IN VITRO DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022-2024 (USD BILLION)
• FIGURE 42 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, 2024
• FIGURE 43 RANKING OF KEY PLAYERS, 2024
• FIGURE 44 EV/EBITDA OF KEY VENDORS, 2025
• FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
• FIGURE 46 IN VITRO DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 47 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 48 IN VITRO DIAGNOSTICS MARKET: COMPANY FOOTPRINT
• FIGURE 49 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 50 DANAHER: COMPANY SNAPSHOT (2024)
• FIGURE 51 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
• FIGURE 52 ABBOTT: COMPANY SNAPSHOT (2024)
• FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
• FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
• FIGURE 55 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 58 BIOMERIEUX: COMPANY SNAPSHOT (2024)
• FIGURE 59 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 60 REVVITY: COMPANY SNAPSHOT (2024)
• FIGURE 61 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
• FIGURE 62 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 63 QIAGEN: COMPANY SNAPSHOT (2024)
• FIGURE 64 DIASORIN S.P.A: COMPANY SNAPSHOT (2023)
• FIGURE 65 GRIFOLS, S.A.: COMPANY SNAPSHOT (2024)
• FIGURE 66 WERFEN: COMPANY SNAPSHOT (2024)
• FIGURE 67 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)

The global In vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6% during the forecast period. This is due to the increasing global burden of chronic diseases such as diabetes, cardiovascular conditions, cancer, and infectious diseases (e.g., HIV, tuberculosis). Demand for faster results, decentralized testing, and home-based diagnostics are pushing growth in point-of-care (POC) testing devices, innovations such as high-throughput systems, lab-on-a-chip, next-generation sequencing (NGS), and POC diagnostics, and government and private sector investments in healthcare infrastructure, especially in developing economies, are improving access to diagnostic services.

The reagents & kits segment is expected to grow at the highest CAGR during the forecast period.

Based on the product, the in vitro diagnostics market is divided into reagents & kits, instruments, and data management software & services. In 2024, the reagents & kits segment grew at the highest CAGR in vitro diagnostics market. This is due to the growing number of tests across hospitals, labs, and home settings, the expansion of rapid and self-testing kits, especially for glucose, pregnancy, and infectious disease detection, the expansion of clinical laboratories, diagnostic chains, and POC testing environments increases reagent usage. Continuous product launches and regulatory approvals-such as CE-IVD marking and FDA clearances-are expanding the portfolio and accessibility of specialized test kits across various clinical applications.

The infectious diseases segment of the in vitro diagnostics market, by application, is expected to hold the largest market share during the forecast period.

Based on application, the in vitro diagnostics market is segmented into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostic, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The infectious disease segment accounts for the largest market share of the in vitro diagnostics market due to the continued prevalence of diseases such as HIV, hepatitis, and tuberculosis, and emerging threats such as Malaria and Mpox, the need for fast, accessible testing-especially in remote or resource-limited settings-has boosted the adoption of portable and easy-to-use IVD kits for infectious diseases, and technologies such as RT-PCR (Reverse transcription polymerase chain reaction) and syndromic panel testing enable accurate, high-throughput diagnosis of multiple pathogens, driving growth in hospital and lab settings.

Asia Pacific is expected to hold the highest CAGR in the in vitro diagnostics market during the forecast period.

The global in vitro diagnostics market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The IVD market in the Asia Pacific region is growing rapidly due to the increasing prevalence of communicable and non-communicable diseases, especially in highly populated countries such as China and India. These countries are seeing a rise in conditions such as diabetes, cancer, cardiovascular diseases, tuberculosis, and hepatitis. Concurrently, the aging population is driving the IVD market in the Asia Pacific region, especially in Japan, South Korea, and China. For instance, within China, 216.76 million people are aged 65 and above, or 15.4% of the population, a 2023 report by China's Ministry of Civil Affairs and the China National Committee on Aging stated. This trend is resulting in a growing demand for chronic disease monitoring and regular diagnostics. In an effort to increase local production and decrease the reliance on imports, regional governments are promoting the manufacture of diagnostic reagents, kits, and equipment locally, thus also fuelling the growth of the market.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1- 42%, Tier 2- 30%, and Tier 3- 28%
• By Designation: C-level- 46%, Director level- 23%, and Others- 31%
• By Region: North America- 23%, Europe- 45%, Asia Pacific- 28%, Latin America- 3%, Middle East & Africa- 0.5%, and GCC Countries- 0.5 %

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the in vitro diagnostics market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMerieux (France), Sysmex Corporation (Japan), Revvity (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Germany), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), and QuidelOrtho Corporation, (US) among others.

Research Coverage

This report studies the in vitro diagnostics market based on product & service, technology, specimen, site of testing, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following points:

• Analysis of key drivers (Increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid PoC technologies and rising adoption of automated analyzers, growing preference for personalized medicines), restraints (Unfavorable reimbursement scenario, stringent regulatory requirements, High cost of diagnostic equipment), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, Improvements in immunoassay diagnostic technologies, digitalization trend), challenges (operational barriers, data privacy, and cybersecurity risks)
• Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the in vitro diagnostics market
• Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the in vitro diagnostics market
• Market Development: Complete knowledge about profitable developing regions
• Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the in vitro diagnostics industry helps to diversify the market
• Competitive Assessment: Comprehensive evaluation of market segmentation, development plans, income analysis, and goods of the top market participants

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Growth forecast
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 PARAMETRIC ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW
• 4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024
• 4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX
• 4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing geriatric population and subsequent rise in chronic diseases
    • 5.2.1.2 Growing awareness of early disease diagnosis in emerging economies
    • 5.2.1.3 Emergence of rapid PoC technologies and rising adoption of automated analyzers
    • 5.2.1.4 Growing preference for personalized medicines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.2.2 Stringent regulatory requirements
    • 5.2.2.3 High cost of diagnostic equipment
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Introduction of disease-specific biomarkers and tests
    • 5.2.3.2 Increasing significance of companion diagnostics
    • 5.2.3.3 Growth opportunities in developing countries
    • 5.2.3.4 Improvements in immunoassay diagnostic technologies
    • 5.2.3.5 Digitalization trend
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Operational barriers
    • 5.2.4.2 Data privacy and cybersecurity risks
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY PRODUCT
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & DEVELOPMENT
  • 5.5.2 RAW MATERIAL SUPPLIERS
  • 5.5.3 MANUFACTURING
  • 5.5.4 DISTRIBUTION, MARKETING, AND SALES
  • 5.5.5 RETAILERS
  • 5.5.6 POST-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Immunohistochemistry
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 382200
  • 5.11.2 EXPORT DATA FOR HS CODE 382200
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE
  • 5.13.2 CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN COMPETITIVE INDIAN MARKET
  • 5.13.3 CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 REGULATORY FRAMEWORK
  • 5.15.1 NORTH AMERICA
    • 5.15.1.1 US
    • 5.15.1.2 Canada
  • 5.15.2 EUROPE
  • 5.15.3 ASIA PACIFIC
    • 5.15.3.1 Japan
    • 5.15.3.2 China
    • 5.15.3.3 India
    • 5.15.3.4 South Korea
    • 5.15.3.5 Indonesia
    • 5.15.3.6 Russia
  • 5.15.4 MIDDLE EAST & AFRICA
    • 5.15.4.1 Saudi Arabia
    • 5.15.4.2 Africa
  • 5.15.5 LATIN AMERICA
    • 5.15.5.1 Mexico
    • 5.15.5.2 Brazil
• 5.16 PORTER'S FIVE FORCES ANALYSIS
  • 5.16.1 BARGAINING POWER OF SUPPLIERS
  • 5.16.2 BARGAINING POWER OF BUYERS
  • 5.16.3 THREAT OF NEW ENTRANTS
  • 5.16.4 THREAT OF SUBSTITUTES
  • 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.17.2 BUYING CRITERIA
• 5.18 RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS
• 5.19 INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES
• 5.20 GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING
• 5.21 IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET
  • 5.21.1 INTRODUCTION
  • 5.21.2 MARKET POTENTIAL OF AI IN IVD DEVICES
  • 5.21.3 AI USE CASES
  • 5.21.4 KEY COMPANIES IMPLEMENTING AI
  • 5.21.5 FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET

6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & KITS
  • 6.2.1 RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH
• 6.3 INSTRUMENTS
  • 6.3.1 GROWING TREND OF AUTOMATION TO DRIVE MARKET
• 6.4 DATA MANAGEMENT SOFTWARE & SERVICES
  • 6.4.1 INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH

7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAYS
  • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
    • 7.2.1.1 Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth
  • 7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
    • 7.2.2.1 Need for minimal human intervention to support growth
  • 7.2.3 IMMUNOFLUORESCENCE ASSAYS
    • 7.2.3.1 Growing introduction of innovative diagnostic platforms to drive market
  • 7.2.4 RAPID TESTS
    • 7.2.4.1 Need for rapid diagnostic tests to expedite growth
  • 7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
    • 7.2.5.1 Need for early detection and monitoring of immune-related disorders to amplify growth
  • 7.2.6 WESTERN BLOTTING
    • 7.2.6.1 Increasing focus on biomarker discovery and personalized treatment to advance growth
  • 7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES
• 7.3 CLINICAL CHEMISTRY
  • 7.3.1 BASIC METABOLIC PANELS
    • 7.3.1.1 Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth
  • 7.3.2 LIVER PANELS
    • 7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to foster growth
  • 7.3.3 RENAL PROFILES
    • 7.3.3.1 Growing awareness for preventive health check-ups to boost market
  • 7.3.4 LIPID PROFILES
    • 7.3.4.1 Rising prevalence of obesity to accelerate growth
  • 7.3.5 THYROID FUNCTION PROFILES
    • 7.3.5.1 High incidence of thyroid-related disorders to support growth
  • 7.3.6 ELECTROLYTE PANELS
    • 7.3.6.1 Growing shift toward home care and remote patient monitoring to fuel market
  • 7.3.7 SPECIALTY CHEMICAL TESTS
    • 7.3.7.1 Rising demand for specialized tests to contribute to growth
• 7.4 MOLECULAR DIAGNOSTICS
  • 7.4.1 POLYMERASE CHAIN REACTION
    • 7.4.1.1 High accuracy and speed in detecting pathogens to aid growth
  • 7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • 7.4.2.1 Growing focus on rapid, onsite molecular diagnostics to propel market
  • 7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    • 7.4.3.1 Growing applications in research, drug discovery, and molecular diagnostics to boost market
  • 7.4.4 IN SITU HYBRIDIZATION
    • 7.4.4.1 Rising prevalence of cancer and genetic disorders to assist growth
  • 7.4.5 DNA MICROARRAYS
    • 7.4.5.1 High resolution and throughput capabilities to favor growth
  • 7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
• 7.5 GLUCOSE MONITORING
  • 7.5.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH
• 7.6 HEMATOLOGY
  • 7.6.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET
• 7.7 MICROBIOLOGY
  • 7.7.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH
• 7.8 COAGULATION & HEMOSTASIS
  • 7.8.1 GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET
• 7.9 BLOOD GAS ANALYZERS
  • 7.9.1 GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET
• 7.10 URINALYSIS
  • 7.10.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH
• 7.11 CHROMATOGRAPHY & MASS SPECTROMETRY
  • 7.11.1 INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH

8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN

• 8.1 INTRODUCTION
• 8.2 BLOOD, SERUM, AND PLASMA SPECIMENS
  • 8.2.1 GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET
• 8.3 SALIVA SPECIMENS
  • 8.3.1 GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TO BOOST MARKET
• 8.4 URINE SPECIMENS
  • 8.4.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH
• 8.5 OTHER SPECIMENS

9 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING

• 9.1 INTRODUCTION
• 9.2 LABORATORY TESTS
  • 9.2.1 INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH
• 9.3 POINT-OF-CARE TESTS
  • 9.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH

10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 INFECTIOUS DISEASES
  • 10.2.1 INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH
• 10.3 ONCOLOGY
  • 10.3.1 RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH
• 10.4 ENDOCRINOLOGY
  • 10.4.1 INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH
• 10.5 CARDIOLOGY
  • 10.5.1 GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET
• 10.6 BLOOD SCREENING
  • 10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH
• 10.7 GENETIC TESTING
  • 10.7.1 INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH
• 10.8 AUTOIMMUNE DISEASES
  • 10.8.1 RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH
• 10.9 ALLERGY DIAGNOSTICS
  • 10.9.1 INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH
• 10.10 DRUG MONITORING & TESTING
  • 10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH
• 10.11 BONE & MINERAL DISORDERS
  • 10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET
• 10.12 COAGULATION TESTING
  • 10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH
• 10.13 BLOOD GROUP TYPING
  • 10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH
• 10.14 OTHER APPLICATIONS

11 IN VITRO DIAGNOSTICS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITALS & CLINICS
  • 11.2.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH
• 11.3 CLINICAL LABORATORIES
  • 11.3.1 LARGE REFERENCE LABORATORIES
    • 11.3.1.1 Growing test volume and complexity of diagnostic testing to propel market
  • 11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES
    • 11.3.2.1 Increasing shift toward community-based and point-of-care settings to foster growth
• 11.4 BLOOD BANKS
  • 11.4.1 NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH
• 11.5 HOME CARE SETTINGS
  • 11.5.1 GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET
• 11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.6.1 INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET
• 11.7 ACADEMIC INSTITUTES
  • 11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH
• 11.8 OTHER END USERS

12 IN VITRO DIAGNOSTICS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market
  • 12.2.3 CANADA
    • 12.2.3.1 Favorable funding initiatives for early disease diagnosis to fuel market
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Increasing investments in clinical diagnostics research to aid growth
  • 12.3.3 FRANCE
    • 12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market
  • 12.3.4 UK
    • 12.3.4.1 Rising adoption of genome-based testing to encourage growth
  • 12.3.5 ITALY
    • 12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to boost market
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing adoption of technologically advanced immunoassay systems to expedite growth
  • 12.3.7 RUSSIA
    • 12.3.7.1 High incidence of respiratory infectious diseases to boost market
  • 12.3.8 SWITZERLAND
    • 12.3.8.1 Growing prevalence of chronic diseases to propel market
  • 12.3.9 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 JAPAN
    • 12.4.2.1 Increasing research investments for immunoassays to encourage growth
  • 12.4.3 CHINA
    • 12.4.3.1 Growing focus on preventive care to boost market
  • 12.4.4 INDIA
    • 12.4.4.1 Rising incidence of diabetes and cancer to augment growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Rising healthcare spending for innovative IVD technologies to amplify growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market
  • 12.4.7 SINGAPORE
    • 12.4.7.1 Rising technological advancements and automation to stimulate growth
  • 12.4.8 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Rising prevalence of diabetes to sustain growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Growing establishment of clinical laboratories to fuel market
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET
  • 12.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
• 12.7 GCC COUNTRIES
  • 12.7.1 GCC COUNTRIES: MACROECONOMIC OUTLOOK
  • 12.7.2 SAUDI ARABIA
    • 12.7.2.1 Rising government healthcare expenditure to boost market
  • 12.7.3 UAE
    • 12.7.3.1 Improvements in healthcare infrastructure to support growth
  • 12.7.4 OTHER GCC COUNTRIES

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 13.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 13.4 REVENUE ANALYSIS, 2022-2024
• 13.5 MARKET SHARE ANALYSIS, 2024
• 13.6 COMPANY VALUATION AND FINANCIAL METRICS
• 13.7 BRAND/PRODUCT COMPARISON
• 13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.8.1 STARS
  • 13.8.2 EMERGING LEADERS
  • 13.8.3 PERVASIVE PLAYERS
  • 13.8.4 PARTICIPANTS
  • 13.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.8.5.1 Company footprint
    • 13.8.5.2 Region footprint
    • 13.8.5.3 Product & service footprint
    • 13.8.5.4 Technology footprint
    • 13.8.5.5 End-user footprint
• 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.9.1 PROGRESSIVE COMPANIES
  • 13.9.2 RESPONSIVE COMPANIES
  • 13.9.3 DYNAMIC COMPANIES
  • 13.9.4 STARTING BLOCKS
  • 13.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.9.5.1 Detailed list of key startups/SMEs
    • 13.9.5.2 Competitive benchmarking of key startups/SMEs
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS
• 13.11 POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET
  • 13.11.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.11.2 DEALS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 DANAHER
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches and approvals
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 F. HOFFMANN-LA ROCHE LTD
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches and approvals
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 ABBOTT
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches and approvals
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weakness and competitive threats
  • 14.1.4 SIEMENS HEALTHINEERS AG
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches and approvals
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Expansions
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 THERMO FISHER SCIENTIFIC INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Deals
      • 14.1.5.3.3 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 ILLUMINA, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches and approvals
      • 14.1.6.3.2 Deals
      • 14.1.6.3.3 Expansions
      • 14.1.6.3.4 Other developments
  • 14.1.7 HOLOGIC, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches and approvals
      • 14.1.7.3.2 Deals
      • 14.1.7.3.3 Expansions
  • 14.1.8 BIO-RAD LABORATORIES, INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches and approvals
      • 14.1.8.3.2 Deals
  • 14.1.9 BIOMERIEUX
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches and approvals
      • 14.1.9.3.2 Deals
      • 14.1.9.3.3 Expansions
  • 14.1.10 SYSMEX CORPORATION
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
  • 14.1.11 REVVITY
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches and approvals
      • 14.1.11.3.2 Deals
      • 14.1.11.3.3 Other developments
  • 14.1.12 BECTON, DICKINSON AND COMPANY
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches and approvals
      • 14.1.12.3.2 Deals
      • 14.1.12.3.3 Expansions
  • 14.1.13 AGILENT TECHNOLOGIES, INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches and approvals
      • 14.1.13.3.2 Deals
      • 14.1.13.3.3 Other developments
  • 14.1.14 QIAGEN
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches and approvals
      • 14.1.14.3.2 Deals
  • 14.1.15 DIASORIN S.P.A.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Product launches and approvals
      • 14.1.15.3.2 Deals
  • 14.1.16 GRIFOLS, S.A.
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products/Services offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Product launches and approvals
      • 14.1.16.3.2 Deals
  • 14.1.17 WERFEN
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products/Services offered
      • 14.1.17.2.1 Deals
      • 14.1.17.2.2 Expansions
  • 14.1.18 QUIDELORTHO CORPORATION
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products/Services offered
    • 14.1.18.3 Recent developments
      • 14.1.18.3.1 Product launches and approvals
      • 14.1.18.3.2 Deals
      • 14.1.18.3.3 Expansions
• 14.2 OTHER PLAYERS
  • 14.2.1 DEVYSER
  • 14.2.2 BIOSYNEX SA
  • 14.2.3 SURMODICS, INC.
  • 14.2.4 MENARINI SILICON BIOSYSTEMS
  • 14.2.5 SPEEDX PTY. LTD.
  • 14.2.6 GENSPEED BIOTECH GMBH
  • 14.2.7 MERCK KGAA
  • 14.2.8 CARIS LIFE SCIENCES
  • 14.2.9 ARKRAY, INC.
  • 14.2.10 ACCELERATE DIAGNOSTICS, INC.
  • 14.2.11 CELLABS
  • 14.2.12 J. MITRA & CO. PVT. LTD.
  • 14.2.13 EPITOPE DIAGNOSTICS, INC.
  • 14.2.14 BOSTER BIOLOGICAL TECHNOLOGY
  • 14.2.15 ENZO BIOCHEM INC.
  • 14.2.16 GENETIC SIGNATURES
  • 14.2.17 SAVYON DIAGNOSTICS
  • 14.2.18 TRIVITRON HEALTHCARE
  • 14.2.19 MDXHEALTH
  • 14.2.20 CREATIVE DIAGNOSTICS
  • 14.2.21 INBIOS INTERNATIONAL, INC.
  • 14.2.22 MACCURA BIOTECHNOLOGY CO., LTD.
  • 14.2.23 LUYE LIFE SCIENCES GROUP

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS